As of 2026-04-09, the EV/EBITDA ratio of Jiangxi Fushine Pharmaceutical Co Ltd (300497.SZ) is -46.74. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 300497.SZ's latest enterprise value is 11,328.74 mil CNY. 300497.SZ's TTM EBITDA according to its financial statements is -242.38 mil CNY. Dividing these 2 quantities gives us the above 300497.SZ EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.1x - 18.7x | 16.4x |
| Forward P/E multiples | 9.4x - 11.6x | 10.6x |
| Fair Price | (9.02) - (0.71) | (5.22) |
| Upside | -147.9% - -103.8% | -127.7% |
| Date | EV/EBITDA |
| 2026-04-03 | -44.32 |
| 2026-04-02 | -46.12 |
| 2026-04-01 | -47.41 |
| 2026-03-31 | -45.25 |
| 2026-03-30 | -48.07 |
| 2026-03-27 | -47.34 |
| 2026-03-26 | -45.90 |
| 2026-03-25 | -43.36 |
| 2026-03-24 | -42.70 |
| 2026-03-23 | -36.41 |
| 2026-03-20 | -38.16 |
| 2026-03-19 | -38.38 |
| 2026-03-18 | -39.27 |
| 2026-03-17 | -39.03 |
| 2026-03-16 | -40.10 |
| 2026-03-13 | -39.61 |
| 2026-03-12 | -40.27 |
| 2026-03-11 | -40.63 |
| 2026-03-10 | -39.65 |
| 2026-03-09 | -39.81 |
| 2026-03-06 | -38.94 |
| 2026-03-05 | -38.83 |
| 2026-03-04 | -38.38 |
| 2026-03-03 | -38.74 |
| 2026-03-02 | -40.43 |
| 2026-02-27 | -41.18 |
| 2026-02-26 | -40.65 |
| 2026-02-25 | -41.67 |
| 2026-02-24 | -40.70 |
| 2026-02-13 | -41.32 |
| 2026-02-12 | -40.76 |
| 2026-02-11 | -40.63 |
| 2026-02-10 | -40.50 |
| 2026-02-09 | -40.01 |
| 2026-02-06 | -40.01 |
| 2026-02-05 | -38.65 |
| 2026-02-04 | -38.67 |
| 2026-02-03 | -38.87 |
| 2026-02-02 | -37.83 |
| 2026-01-30 | -38.52 |
| 2026-01-29 | -39.43 |
| 2026-01-28 | -40.47 |
| 2026-01-27 | -41.14 |
| 2026-01-26 | -41.47 |
| 2026-01-23 | -43.61 |
| 2026-01-22 | -42.14 |
| 2026-01-21 | -42.38 |
| 2026-01-20 | -42.61 |
| 2026-01-19 | -43.52 |
| 2026-01-16 | -41.72 |